StonvexLoading…
StonvexStonvexStonvexCore line items from WELL's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-07-27 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $3.35B | $2.78B | $8.45B | $5.90B | $3.84B |
Operating Income | Not available | $345.24M | Not available | $790.03M | $496.92M |
Net Income | Not available | $752.32M | $961.84M | $844.07M | $561.88M |
EPS (Diluted) | $0.69 | $1.02 | $1.39 | $1.26 | $0.85 |
Total Assets | Not available | $67.22B | $67.30B | $59.50B | $55.83B |
Total Liabilities | Not available | $22.29B | $24.10B | $20.19B | $19.29B |
Cash & Equivalents | Not available | $4.70B | $5.03B | $6.81B | $4.41B |
Free Cash Flow OCF − CapEx | Not available | $400.18M | $1.83B | $1.49B | $895.76M |
Shares Outstanding | Not available | 704.69M | 696.51M | 684.11M | 665.12M |